Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: Results of the HGF-0205 trial Richard J. Powell, MD, Phillip Goodney, MD, Farrell O. Mendelsohn, MD, Elaine K. Moen, MD, Brian H. Annex, MD Journal of Vascular Surgery Volume 52, Issue 6, Pages 1525-1530 (December 2010) DOI: 10.1016/j.jvs.2010.07.044 Copyright © 2010 Society for Vascular Surgery Terms and Conditions
Fig 1 Example of severity of tissue loss in two patients enrolled into HGF-0205 Trial. Journal of Vascular Surgery 2010 52, 1525-1530DOI: (10.1016/j.jvs.2010.07.044) Copyright © 2010 Society for Vascular Surgery Terms and Conditions
Fig 2 Toe brachial index at baseline and 3 and 6 months following first injections (solid columns) compared with placebo (hatched columns). Data presented as mean ± standard error. Journal of Vascular Surgery 2010 52, 1525-1530DOI: (10.1016/j.jvs.2010.07.044) Copyright © 2010 Society for Vascular Surgery Terms and Conditions
Fig 3 Pain measured as visual analogue scale (VAS) at baseline and 3 and 6 months following first injections (solid columns) compared with placebo (hatched columns). Data presented as mean ± standard error. Journal of Vascular Surgery 2010 52, 1525-1530DOI: (10.1016/j.jvs.2010.07.044) Copyright © 2010 Society for Vascular Surgery Terms and Conditions